^
    6d
    24-Week Recurrence Rate of Gout Following Firsekibart Treatment (clinicaltrials.gov)
    P=N/A, N=264, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial • Real-world evidence
    |
    Jin Beixin (firsekibart)
    9d
    Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial (clinicaltrials.gov)
    P=N/A, N=118, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial
    |
    Jin Beixin (firsekibart)
    2ms
    A multicenter, prospective, basket interventional study of vixencizumab in the treatment of CAPS, FMF, Schnitzler syndrome and AOSD (ChiCTR2600120336)
    P=N/A, N=90, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    New trial
    |
    NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    Jin Beixin (firsekibart)
    2ms
    Clinical trial on the Efficacy and Safety of an IL‑1 Inhibitor in Elderly Patients With Gouty Arthritis (ChiCTR2600119982)
    P4, N=22, Hebei General Hospital; Hebei General Hospital
    New P4 trial
    |
    Jin Beixin (firsekibart)
    2ms
    Clinical Effectiveness and Safety of IL-1 Inhibitors Plus Urate-Lowering Therapy Compared to Conventional Treatment in Patients with Refractory Gout: A Real-World Study (ChiCTR2600119208)
    P=N/A, N=56, Tianjin Medical University Chu Hsien-I Memorial Hospital; Tianjin Medical University Chu Hsien-I Memorial?Hospital
    New trial • Real-world evidence
    |
    Jin Beixin (firsekibart)
    2ms
    A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, Tongji Hospital
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Jin Beixin (firsekibart)
    2ms
    A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jin Beixin (firsekibart) • Kineret (anakinra)
    2ms
    Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Tongji Hospital
    New trial
    |
    Jin Beixin (firsekibart)
    7ms
    Efficacy and Safety of Firsekibart versus Anakinra in Adult-Onset Still's Disease (ChiCTR2500109835)
    P4, N=20, Not yet recruiting, Ruijin Hospital, Shanghai JiaoTong University School of Medicine; Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai
    New P4 trial
    |
    Jin Beixin (firsekibart) • Kineret (anakinra)
    9ms
    A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Ruijin Hospital
    New trial
    |
    Jin Beixin (firsekibart) • Kineret (anakinra)
    1year
    Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults (clinicaltrials.gov)
    P1, N=24, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    Jin Beixin (firsekibart)
    over1year
    Clinical Study of Genakumab for Injection in Patients With Acute Gout (clinicaltrials.gov)
    P1/2, N=121, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Jin Beixin (firsekibart)